Legal & General Group Plc Buys Shares of 888,490 Avantor, Inc. $AVTR

Legal & General Group Plc bought a new stake in Avantor, Inc. (NYSE:AVTR) in the second quarter, Holdings Channel.com reports. The institutional investor bought 888,490 shares of the company’s stock, valued at approximately $8,796,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. EverSource Wealth Advisors LLC grew its holdings in shares of Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after buying an additional 1,189 shares in the last quarter. Strategic Wealth Investment Group LLC purchased a new stake in Avantor in the 2nd quarter worth about $32,000. Los Angeles Capital Management LLC purchased a new stake in Avantor in the 4th quarter worth about $32,000. Osaic Holdings Inc. boosted its position in Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after acquiring an additional 1,064 shares during the period. Finally, SJS Investment Consulting Inc. boosted its position in Avantor by 1,599.7% during the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after acquiring an additional 4,927 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on AVTR shares. Stifel Nicolaus upped their target price on Avantor from $8.00 to $15.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Wall Street Zen upgraded shares of Avantor from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Morgan Stanley boosted their price objective on shares of Avantor from $10.00 to $14.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Wells Fargo & Company boosted their price objective on shares of Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Finally, UBS Group set a $8.00 price objective on shares of Avantor in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $12.00.

Avantor Stock Performance

Shares of NYSE AVTR opened at $14.23 on Wednesday. The business’s 50-day moving average price is $12.32 and its two-hundred day moving average price is $9.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. Avantor, Inc. has a one year low of $7.26 and a one year high of $15.93. The company has a market capitalization of $9.62 billion, a P/E ratio of -16.94, a price-to-earnings-growth ratio of 10.97 and a beta of 0.89.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The company had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same period in the prior year, the firm posted $0.24 EPS. The business’s revenue was up .5% compared to the same quarter last year. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Analysts anticipate that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.